How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
60
AZN Quote, Financials, Valuation and Earnings
Last price:
$92.79
Seasonality move
:
3.98%
Day range:
$92.57 - $93.53
52-week range:
$61.24 - $96.51
Dividend yield:
1.69%
P/E ratio:
30.75x
P/S ratio:
4.98x
P/B ratio:
6.26x
Volume:
6.5M
Avg. volume:
7.5M
1-year change:
31.8%
Market cap:
$287.1B
Revenue:
$54.1B
EPS (TTM):
$3.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$15.4B | $1.08 | 6.7% | 30.88% | $100.96 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
GSK
GSK Plc
|
$11.7B | $0.62 | 9.29% | 22.2% | $52.35 |
|
MREO
Mereo BioPharma Group Plc
|
$7.1M | -$0.01 | -100% | -75.07% | $3.45 |
|
MRNA
Moderna, Inc.
|
$620M | -$2.73 | 131.45% | -7.51% | $37.70 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.8B | $10.74 | 12.61% | 35.87% | $831.38 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$92.59 | $100.96 | $287.1B | 30.75x | $0.52 | 1.69% | 4.98x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$1.84 | $17.94 | $1.5M | -- | $0.00 | 0% | 0.73x |
|
GSK
GSK Plc
|
$50.66 | $52.35 | $101.8B | 14.45x | $0.43 | 3.34% | 2.48x |
|
MREO
Mereo BioPharma Group Plc
|
$0.44 | $3.45 | $70M | -- | $0.00 | 0% | 137.39x |
|
MRNA
Moderna, Inc.
|
$46.86 | $37.70 | $18.3B | -- | $0.00 | 0% | 8.13x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$749.44 | $831.38 | $78.8B | 17.94x | $0.88 | 0.47% | 5.80x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
41.56% | 0.018 | 13.71% | 0.66x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.608 | -- | 1.20x |
|
GSK
GSK Plc
|
52.36% | -0.215 | 27.67% | 0.53x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 1.603 | 0.12% | 8.09x |
|
MRNA
Moderna, Inc.
|
7.29% | 0.833 | 7.28% | 3.30x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | -0.094 | 4.57% | 3.19x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$11.2B | $3.6B | 12.62% | 22.01% | 23.52% | $3.5B |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
GSK
GSK Plc
|
$8.5B | $3.5B | 19.21% | 42.84% | 30.08% | $1.8B |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
MRNA
Moderna, Inc.
|
$757M | -$260M | -27.85% | -30.18% | -25.59% | -$880M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of 16.69% compared to AstraZeneca PLC's net margin of --. AstraZeneca PLC's return on equity of 22.01% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About AZN or BDRX?
AstraZeneca PLC has a consensus price target of $100.96, signalling upside risk potential of 9.04%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 9565.83%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than AstraZeneca PLC, analysts believe Biodexa Pharmaceuticals Plc is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is AZN or BDRX More Risky?
AstraZeneca PLC has a beta of 0.335, which suggesting that the stock is 66.49% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.952, suggesting its less volatile than the S&P 500 by 4.8%.
-
Which is a Better Dividend Stock AZN or BDRX?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.69%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or BDRX?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. AstraZeneca PLC's net income of $2.5B is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.75x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.98x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.98x 30.75x $15.1B $2.5B BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns AZN or GSK?
GSK Plc has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 25.09%. AstraZeneca PLC's return on equity of 22.01% beat GSK Plc's return on equity of 42.84%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B GSKGSK Plc73.8% $1.32 $45.1B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of $100.96, signalling upside risk potential of 9.04%. On the other hand GSK Plc has an analysts' consensus of $52.35 which suggests that it could grow by 3.34%. Given that AstraZeneca PLC has higher upside potential than GSK Plc, analysts believe AstraZeneca PLC is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 GSKGSK Plc1 5 1 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.335, which suggesting that the stock is 66.49% less volatile than S&P 500. In comparison GSK Plc has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.665%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.69%. GSK Plc offers a yield of 3.34% to investors and pays a quarterly dividend of $0.43 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. GSK Plc pays out 94.89% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than GSK Plc quarterly revenues of $11.5B. AstraZeneca PLC's net income of $2.5B is lower than GSK Plc's net income of $2.9B. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.75x while GSK Plc's PE ratio is 14.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.98x versus 2.48x for GSK Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.98x 30.75x $15.1B $2.5B GSKGSK Plc2.48x 14.45x $11.5B $2.9B
-
Which has Higher Returns AZN or MREO?
Mereo BioPharma Group Plc has a net margin of 16.69% compared to AstraZeneca PLC's net margin of -2923.31%. AstraZeneca PLC's return on equity of 22.01% beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About AZN or MREO?
AstraZeneca PLC has a consensus price target of $100.96, signalling upside risk potential of 9.04%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $3.45 which suggests that it could grow by 500.42%. Given that Mereo BioPharma Group Plc has higher upside potential than AstraZeneca PLC, analysts believe Mereo BioPharma Group Plc is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 MREOMereo BioPharma Group Plc4 2 0 -
Is AZN or MREO More Risky?
AstraZeneca PLC has a beta of 0.335, which suggesting that the stock is 66.49% less volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.214%.
-
Which is a Better Dividend Stock AZN or MREO?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.69%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MREO?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Mereo BioPharma Group Plc quarterly revenues of --. AstraZeneca PLC's net income of $2.5B is higher than Mereo BioPharma Group Plc's net income of -$7M. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.75x while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.98x versus 137.39x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.98x 30.75x $15.1B $2.5B MREOMereo BioPharma Group Plc137.39x -- -- -$7M
-
Which has Higher Returns AZN or MRNA?
Moderna, Inc. has a net margin of 16.69% compared to AstraZeneca PLC's net margin of -19.69%. AstraZeneca PLC's return on equity of 22.01% beat Moderna, Inc.'s return on equity of -30.18%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B MRNAModerna, Inc.74.51% -$0.51 $10.1B -
What do Analysts Say About AZN or MRNA?
AstraZeneca PLC has a consensus price target of $100.96, signalling upside risk potential of 9.04%. On the other hand Moderna, Inc. has an analysts' consensus of $37.70 which suggests that it could fall by -19.55%. Given that AstraZeneca PLC has higher upside potential than Moderna, Inc., analysts believe AstraZeneca PLC is more attractive than Moderna, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 MRNAModerna, Inc.2 18 1 -
Is AZN or MRNA More Risky?
AstraZeneca PLC has a beta of 0.335, which suggesting that the stock is 66.49% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.991%.
-
Which is a Better Dividend Stock AZN or MRNA?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.69%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MRNA?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Moderna, Inc. quarterly revenues of $1B. AstraZeneca PLC's net income of $2.5B is higher than Moderna, Inc.'s net income of -$200M. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.75x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.98x versus 8.13x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.98x 30.75x $15.1B $2.5B MRNAModerna, Inc.8.13x -- $1B -$200M
-
Which has Higher Returns AZN or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 38.89%. AstraZeneca PLC's return on equity of 22.01% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About AZN or REGN?
AstraZeneca PLC has a consensus price target of $100.96, signalling upside risk potential of 9.04%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $831.38 which suggests that it could grow by 10.93%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than AstraZeneca PLC, analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 REGNRegeneron Pharmaceuticals, Inc.17 8 0 -
Is AZN or REGN More Risky?
AstraZeneca PLC has a beta of 0.335, which suggesting that the stock is 66.49% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.
-
Which is a Better Dividend Stock AZN or REGN?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.69%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.47% to investors and pays a quarterly dividend of $0.88 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or REGN?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. AstraZeneca PLC's net income of $2.5B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.75x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.98x versus 5.80x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.98x 30.75x $15.1B $2.5B REGNRegeneron Pharmaceuticals, Inc.5.80x 17.94x $3.8B $1.5B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 66x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
67
PFSI alert for Jan 30
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Buy
78
GDXU alert for Jan 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Buy
88
JNUG alert for Jan 30
Direxion Daily Junior Gold Miners Idx Bull 2X Shs [JNUG] is down 26.98% over the past day.
